MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma. 2020

Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
Department of Technological Innovation and Safety of Plants, Product and Anthropic Settlements (DIT), Italian Workers' Compensation Authority (INAIL), Rome, Italy.

Malignant mesothelioma is an aggressive tumor resistant to current therapies with a latency period ranging between 20 and 60 years, caused by inhalation of asbestos fibers, that continues to represent a social and healthcare issue. The high percentage of people exposed to asbestos for professional or environmental reasons is associated with the high biopersistence of its fibers and with its widespread use in the last century. Approximately 20-40% of men report an occupational history that might have caused the workplace exposure (criteria Helsinki, 1997). Some authors are evaluating the possible use of bioindicators as a screening and early diagnosis tool. In this regard, the use of microRNAs has been proposed as powerful diagnostic and prognostic biomarkers for many tumors and human diseases. This review focuses on the current state of knowledge on the key role of microRNAs expression as new malignant mesothelioma biomarkers, in early clinical diagnostic applications.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008654 Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) Mesotheliomas
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086002 Mesothelioma, Malignant A type of mesothelioma with a tendency to metastasize. Most tumors originate from either the PLEURA or PERITONEUM, tumors may also originate in the PERICARDIUM or testicular tissue. It is associated with ASBESTOS exposure. Somatic mutations identified in WT1, BCL10, CDKN2A, NF2, and BAP1 genes are associated with the malignancy. OMIM: 156240. Malignant Mesothelioma,Malignant Pleural Mesothelioma,Mesothelioma, Malignant Pleural,Malignant Mesotheliomas,Malignant Pleural Mesotheliomas,Mesotheliomas, Malignant,Mesotheliomas, Malignant Pleural,Pleural Mesothelioma, Malignant,Pleural Mesotheliomas, Malignant
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001194 Asbestos Asbestos. Fibrous incombustible mineral composed of magnesium and calcium silicates with or without other elements. It is relatively inert chemically and used in thermal insulation and fireproofing. Inhalation of dust causes asbestosis and later lung and gastrointestinal neoplasms.
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016273 Occupational Exposure The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation. Exposure, Occupational,Exposures, Occupational,Occupational Exposures

Related Publications

Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
November 2021, Journal of personalized medicine,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
January 2021, Thoracic cancer,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
October 2000, Advances in clinical pathology : the official journal of Adriatic Society of Pathology,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
February 2008, Bulletin du cancer,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
April 2013, Genes, chromosomes & cancer,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
July 2005, Lung cancer (Amsterdam, Netherlands),
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
September 2013, Cancer biology & medicine,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
March 2003, Current opinion in oncology,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
June 2017, Translational lung cancer research,
Elena Sturchio, and Maria Grazia Berardinelli, and Priscilla Boccia, and Miriam Zanellato, and Silvia Gioiosa
April 2018, BMC pulmonary medicine,
Copied contents to your clipboard!